

# CITATION REPORT

List of articles citing

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

DOI: 10.1136/heart.85.3.265

British Heart Journal, 2001, 85, 265-71.

**Source:** <https://exaly.com/paper-pdf/32579473/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
291	Aspirin for primary prevention: Consider the risk 2001, 5, 45-50		
290	Docetaxel induced cardiotoxicity. <i>British Heart Journal</i> , 2001, 86, 219		19
289	Coronary event risk needs to be quantified before advising aspirin for primary prevention. 2001, 2, 1		
288	Pharmacoepidemiology and drug safety. 2001, 10, 345-60		
287	Aspirin is safe and effective for CHD primary prevention where coronary event risk is greater than 1.5% per year. 2001, 5, 95-96		
286	Altered CD18 leucocyte integrin expression and adhesive function in patients with an acute coronary syndrome. <i>British Heart Journal</i> , 2001, 85, 702-4		5
285	A National Service Framework for diabetes. 2001, 1, 123-125		0
284	The relationship between infection, inflammation, and cardiovascular disease: an overview. 2001, 6, 1-8		92
283	Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease. <i>British Heart Journal</i> , 2001, 86, 217-20		9
282	The silent sextet. 2001, 1, 3-6		4
281	Acute pressure overload cardiac arrhythmias are dependent on the presence of myocardial tissue catecholamines. <i>British Heart Journal</i> , 2001, 85, 576		10
280	Vascular disease and survival in patients with type 2 diabetes and nephropathy. 2002, 2, 137-142		1
279	Use of statins and aspirin to reduce risks of cardiovascular disease. 2002, 7, 77-80		15
278	Acetaminophen, aspirin, and renal failure. 2002, 346, 1588-9; author reply 1588-9		4
277	Clinical practice. Aspirin for primary prevention of coronary events. 2002, 346, 1468-74		123
276	Review: Which patients with diabetes should receive which antiplatelet agents?. 2002, 2, 157-160		0
275	Use of nonopioid analgesics and adjunctive agents in the management of pain in rheumatic diseases. 2002, 14, 63-71		18

274	Hemorrhagic complications of oculoplastic surgery. <b>2002</b> , 18, 409-15	30
273	Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods. <b>2002</b> , 20, 2173-82	17
272	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. <b>2002</b> , 16, 1371-81	80
271	Anti-inflammatory and antipyretic analgesics and drugs used in gout. <b>2002</b> , 25, 126-138	
270	Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. <b>2002</b> , 20, 2301-7	48
269	Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. <b>2002</b> , 122, 78-84	65
268	Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?. <b>2002</b> , 25, 829-35	16
267	Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. <b>2002</b> , 19, 633-46	8
266	Cardiovascular hazard of selective COX-2 inhibitors: myth or reality?. <b>2002</b> , 1, 45-52	9
265	Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. <b>2002</b> , 108, 115-9	54
264	The placebo effect and randomized trials: analysis of alternative medicine. <b>2002</b> , 29, 135-55, x	8
263	[Benefits and risks of cyclooxygenase-2-selective inhibitor nonsteroidal antiinflammatory drugs]. <b>2002</b> , 119, 429-34	5
262	Chemoprevention of colorectal cancer: problems, progress, and prospects. <b>2002</b> , 31, 971-99	18
261	Aspirina en la prevenci3n primaria del paciente hipertenso. <b>2002</b> , 202, 652-654	1
260	The Impact of NSAIDs on the Risk of Coronary Heart Disease. <b>2002</b> , 37, 919-926	
259	Primary and Secondary Prevention of Coronary Heart Disease. <b>2002</b> , 30, 59-64	1
258	Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. <b>2002</b> , 89, 26D-32D	93
257	Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. <b>2002</b> , 37, 925-9	23

256	The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. <b>2002</b> , 47, 349-55	54
255	Primaire preventie van vasculaire aandoeningen met behulp van een lage dosis acetylsalicylzuur?. <b>2002</b> , 40, 92-93	
254	The public health potential of aspirin. <b>2002</b> , 91, 49-50	11
253	Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?. <b>2002</b> , 50, 1293-6	18
252	Measurement of thrombosis and its prevention. <b>2002</b> , 54, 96-100	9
251	Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003?. <b>2003</b> , 11, 337-54	5
250	Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: Chronic platelet activation in diabetic heart patients. <b>2003</b> , 17, 269-78	11
249	Antiplatelet therapy in peripheral arterial disease. Consensus statement. <b>2003</b> , 26, 1-16	53
248	Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient. <b>2003</b> , 55, 282-7	11
247	Ensuring the quality of diabetes care: Use of the QUAD-CAT model and Alphabet Strategy in clinical practice. <b>2003</b> , 20, 171-177	0
246	Scientific and therapeutic advances in antiplatelet therapy. <b>2003</b> , 2, 15-28	288
245	[Use of anti-aggregant drugs in primary and secondary cardiovascular prevention in diabetics in town and country in the Leñ area]. <b>2003</b> , 31, 361-5	2
244	Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. <b>2003</b> , 26, 49-54	8
243	Benefit-risk analysis : a brief review and proposed quantitative approaches. <b>2003</b> , 26, 853-62	29
242	Mandate to modify a medicinal mantra: maybe not yet?. <b>2003</b> , 124, 842-4	4
241	Cancer and the Cyclo-Oxygenase Enzyme. <b>2003</b> , 2, 27-55	11
240	Management of stable angina. <b>2003</b> , 79, 332-6	5
239	Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. <b>2003</b> , 52, 1598-601	26

238	Initiating antiplatelet therapy in diabetes: a PCO view. <b>2003</b> , 3, 349-353	0
237	Diabetes services in primary care: are we prepared for the diabetes NSF?. <b>2003</b> , 3, 418-423	0
236	Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?. <b>2003</b> , 34, 2736-40	17
235	The role of aspirin in cardiovascular diseases--forgotten benefits?. <b>2004</b> , 5, 109-15	16
234	Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. <b>2004</b> , 96, 316-25	59
233	COX-2 and the cardiovascular system. <b>2004</b> , 161-178	
232	Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <b>2004</b> , 126, 513S-548S	170
231	Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. <b>2004</b> , 27, 2752-4	18
230	Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. <b>2004</b> , 21, 238-45	45
229	Cardiac medications and their association with cardiovascular events in incident dialysis patients: cause or effect?. <b>2004</b> , 65, 1017-25	39
228	Cost-effectiveness of screening for coronary artery disease in asymptomatic patients with Type 2 diabetes and additional atherogenic risk factors. <i>Journal of General Internal Medicine</i> , <b>2004</b> , 19, 1181-91 <sup>4</sup>	27
227	Review article: appropriate use of proton pump inhibitors with traditional nonsteroidal anti-inflammatory drugs and COX-2 selective inhibitors. <b>2004</b> , 19 Suppl 1, 60-5	23
226	The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. <b>2004</b> , 28, 51-63	270
225	[Epidemiology of digestive complications associated with use of low-dose aspirin]. <b>2004</b> , 28 Spec No 3, C37-44	3
224	Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. <b>2004</b> , 24, 1037-49	1
223	[Selective cyclooxygenase-2 inhibitors for postoperative pain therapy. Analgesic efficacy and adverse effects]. <b>2004</b> , 53, 1211-8	1
222	Perceptions of cardiovascular risk among patients with hypertension or diabetes. <b>2004</b> , 52, 47-53	86
221	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. <b>2004</b> , 101, 189-97	17

220	Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. <b>2004</b> , 4, 87-106		21
219	Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. <i>Revista Espanola De Cardiologia</i> , <b>2004</b> , 57, 963-980	1.5	0
218	Cartas al editor. <b>2004</b> , 123, 239		
217	Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?. <i>Journal of Vascular Surgery</i> , <b>2004</b> , 40, 691-7	3.5	42
216	Management of metabolic syndrome: aspirin. <b>2004</b> , 33, 577-93, vii		17
215	<i>Helicobacter pylori</i> infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. <b>2004</b> , 36, 666-70		33
214	Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. <b>2004</b> , 43, 519-25		86
213	Foundation and sites of action of antithrombotic agents. <b>2004</b> , 17, 3-22		7
212	Aspirin for primary prevention of coronary heart disease. <b>2004</b> ,		1
211	Meta analysis finds strong evidence that aspirin reduces the risk of first myocardial infarction. <b>2004</b> , 8, 8-9; discussion 10-1		
210	Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <b>2004</b> , 148, 263-8		171
209	Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. <b>2004</b> , 117, 528-30		11
208	Current and future concepts in stroke prevention. <b>2004</b> , 170, 1123-33		19
207	Aspirin for the primary prevention of cardiovascular disease: a comprehensive review. <b>2005</b> , 31, 186-93		8
206	Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: yes. <b>2005</b> , 3, 632-4		16
205	Aspirin resistance. <b>2005</b> , 3, 1655-62		61
204	Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. <b>2005</b> , 25, 847-61		4
203	Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?. <b>2005</b> , 61, 595-601		10

202	Aspirin and Cardiovascular Prevention in the Guidelines and in the Real World. <b>2005</b> , 63-74		
201	ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events. <b>2005</b> , 62, 1398-405		5
200	Risk of hemorrhagic stroke with aspirin use: an update. <b>2005</b> , 36, 1801-7		129
199	Analysis of aspirin-associated risks in healthy individuals. <i>Annals of Pharmacotherapy</i> , <b>2005</b> , 39, 51-7	2.9	5
198	Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?. <b>2005</b> , 2, 290-300		33
197	What's So Good About Aging?. <b>2005</b> , 2, 103-114		1
196	Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents. <b>2005</b> , 10, 153-61		19
195	Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. <b>2005</b> , 365, 176-86		632
194	JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. <b>2005</b> , 91 Suppl 5, v1-52		523
193	Low-dose aspirin for the prevention of atherothrombosis. <b>2005</b> , 353, 2373-83		870
192	Women's health study (aspirin) and TNT. <b>2005</b> , 8, 181-5		
191	A health impact assessment of increased aspirin use in Wales. <b>2005</b> , 119, 734-7		5
190	A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. <b>2005</b> , 150, 401		27
189	The Vioxx debacle revisited. <b>2005</b> , 118, 1057-8		
188	Aspirin use for the primary prevention of coronary heart disease in older adults. <b>2005</b> , 118, 1288		18
187	Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update. <b>2005</b> , 65, 433-45		7
186	Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. <b>2005</b> , 48, 4061-7		94
185	Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus : management strategies. <b>2005</b> , 4, 75-86		8

184	Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin. <b>2006</b> , 66 Suppl 1, 23-8; discussion 29-33	6
183	El tratamiento con aspirina es coste-efectivo en la prevención primaria de la enfermedad coronaria y la adición de una estatina es coste-efectiva dependiendo del riesgo. <b>2006</b> , 13, 499	
182	Cardioprotective medication use in hemodialysis patients. <i>Canadian Journal of Cardiology</i> , <b>2006</b> , 22, 755-60	36
181	Antiplatelet agents and arterial thrombosis. <b>2006</b> , 22, 57-74, viii	3
180	Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. <b>2006</b> , 11, 170-6	32
179	Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. <b>2006</b> , 5, 83-94	24
178	Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. <b>2006</b> , 119, 552-9	57
177	Aspirin overprescription in primary cardiovascular prevention. <b>2006</b> , 118, 471-7	16
176	Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. <b>2006</b> , 84, 561-9	82
175	Are the new Joint British Societies 2 (JBS 2) targets achievable?. <b>2006</b> , 23, 283-286	0
174	Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/beta-catenin signal pathway. <b>2006</b> , 33, 696-701	35
173	Prevention of cardiovascular complications of diabetes mellitus by aspirin. <b>2004</b> , 22, 215-26	12
172	A cost-effectiveness analysis of n-3 PUFA (Omacor) treatment in post-MI patients. <b>2006</b> , 60, 922-32	11
171	Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen?. <b>2006</b> , 98, 275-80	24
170	The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. <b>2006</b> , 23, 1489-98	39
169	Measurement of salicylic acid in human serum using stable isotope dilution and gas chromatography-mass spectrometry. <b>2006</b> , 354, 274-8	17
168	Prevention of vascular events in patients with cerebrovascular disease: efficacy and appropriate duration of antiplatelet therapy. <b>2006</b> , 29, 244-8	2
167	Pain management today - what have we learned?. <b>2006</b> , 25 Suppl 1, S2-8	60



166	Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. <b>2006</b> , 62, 145-154		21
165	Prevention of cardiovascular disease in patients with rheumatic diseases. <b>2006</b> , 20, 741-56		5
164	Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. <b>2006</b> , 4, 22		130
163	Cardiovascular risks of cyclooxygenase inhibition. <b>2006</b> , 26, 919-38		8
162	Novel aspects of eicosanoid signaling through the use of gene-targeted mice. <b>2006</b> , 50, 33-38		
161	Review: Aspirin and diabetes. <b>2006</b> , 6, 74-82		1
160	Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies. <b>2006</b> , 38, 415-28		82
159	Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. <b>2006</b> , 20, 2468-75		60
158	My health: whose responsibility? Low-dose aspirin and older people. <i>Expert Review of Cardiovascular Therapy</i> , <b>2006</b> , 4, 755-64	2.5	1
157	Chapter 1: Introduction. <b>2007</b> , 14, S2-S113		
156	Circulating salicylic acid is related to fruit and vegetable consumption in healthy subjects. <b>2007</b> , 98, 802-6		19
155	Aspirin and bleeding in dentistry: an update and recommendations. <b>2007</b> , 104, 316-23		45
154	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. <b>2007</b> , 17, 32-40		11
153	Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. <b>2007</b> , 118, 88-96		21
152	Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. <b>2007</b> , 370, 2138-51		111
151	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <b>2007</b> , 16, 135-232		247
150	Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective. <b>2007</b> , 25, 1063-82		20
149	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. <i>Revista Espanola De Cardiologia</i> , <b>2007</b> , 60, 968.e1-94	1.5	29

148	O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies. <b>2007</b> , 15, 4767-74	61
147	Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain. <b>2007</b> , 8, 60	4
146	Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). <b>2007</b> , 50, 602-11	94
145	Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. <b>2007</b> , 27, 477-82	10
144	Thrombozytenfunktion bei Diabetes mellitus. <b>2008</b> , 4, 429-434	
143	Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. <b>2008</b> , 28, 1249-58	16
142	Heart health and diet. <b>2008</b> , 108, 34	
141	Chapter 18 Gastrointestinal Complications of Anti-Rheumatic Drugs. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 243-275	0.3 1
140	Dual antithrombotic therapy and hypercoagulability in diabetic patients. <b>2008</b> , 155, e47; author reply e49	
139	Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. <b>2008</b> , 46, 137-44	24
138	Antiplatelet agents and arterial thrombosis. <b>2008</b> , 26, 189-201, vi	8
137	Aspirin: promise and resistance in the new millennium. <b>2008</b> , 28, s25-32	72
136	Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. <b>2008</b> , 5, 138-44	83
135	Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. <b>2008</b> , 103, 2432-42	15
134	Risk factors for unintentional injuries in children: are grandparents protective?. <b>2008</b> , 122, e980-7	29
133	Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. <b>2008</b> , 17, 1858-61	18
132	Targeted versus global approaches to the management of hypercholesterolaemia. <b>2008</b> , 128, 248-54	3
131	Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. <b>2008</b> , 117, 2875-83	75

130	The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <b>2008</b> , 133, 776S-814S		196
129	The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. <i>BMJ, The</i> , <b>2008</b> , 337, a1840	5,9	629
128	Heart rate variability in patients with stable coronary artery disease and aspirin resistance. <b>2008</b> , 49, 413-22		6
127	Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding. <b>2009</b> , 23, 619-23		10
126	Relationship between Disgust and Memory Biases in Spider Fear. <b>2009</b> , 2, 16-36		3
125	An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. <b>2009</b> , 103, 1227-37		99
124	Efecto de dosis bajas de aspirina y antioxidantes en la progresi3n de la enfermedad cardiovascular en diab3ticos con arteriopat3a perif3rica asintom3tica. <b>2009</b> , 16, 454		
123	Patient preferences for the chemoprevention of colorectal cancer. <b>2009</b> , 54, 2207-14		4
122	Aspirin for primary prevention in diabetes?. <b>2009</b> , 26, 6-8		1
121	Synthesis of new nitroxyalkylamides as potential prototypes of hybrid nonsteroidal anti-inflammatory drugs containing NO-donating fragment. <b>2009</b> , 425, 88-90		2
120	[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?]. <b>2009</b> , 30, 1001-3		
119	Prediction of 10-year coronary heart disease risk in Caribbean type 2 diabetic patients using the UKPDS risk engine. <b>2009</b> , 132, 348-53		6
118	Luteal support: progestogens for pregnancy protection. <b>2009</b> , 65 Suppl 1, S29-34		45
117	[Primary and secondary prevention of stroke: a guideline]. <b>2009</b> , 133, 754-62		8
116	[European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish Adaptation]. <b>2009</b> , 41, 463.e1-463.e24		1
115	Gu3a Europea de Prevenci3n Cardiovascular en la Pr3ctica Cl3nica. Adaptaci3n espa3ola del CEIPC 2008. <b>2009</b> , 209, 279-302		11
114	Gu3a Europea de Prevenci3n Cardiovascular en la Pr3ctica Cl3nica. Adaptaci3n espa3ola del CEIPC 2008. <b>2009</b> , 26, 157-180		2
113	Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. <b>2009</b> , 204, e58-63		59

112	Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. <i>Semergen</i> , <b>2009</b> , 35, 66-85	1.9	1
111	Aspirin, salicylates, and cancer. <b>2009</b> , 373, 1301-9		231
110	Aspirin in the primary prevention of vascular disease. <b>2009</b> , 374, 878-9; author reply 879		1
109	Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008. <b>2009</b> , 21, 124-150		3
108	Aspirin for the prevention of cardiovascular disease: systematic review. <b>2010</b> , 25, 17-21		5
107	Management of cardiovascular complications in systemic lupus erythematosus. <b>2010</b> , 5, 75-100		24
106	Plasma salicylate level and aspirin resistance in survivors of myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2010</b> , 29, 416-20	5.1	3
105	Effect of chronic Aspirin therapy on angiographic thrombotic burden in patients admitted for a first ST-elevation myocardial infarction. <b>2010</b> , 105, 587-91		28
104	Antiplatelet drug interactions. <b>2010</b> , 268, 516-29		26
103	Thromboxane and the thromboxane receptor in cardiovascular disease. <b>2010</b> , 5, 209-219		71
102	Potential economic impact of increasing low dose aspirin usage on CVD in the US. <b>2010</b> , 26, 2365-73		7
101	Uso de antiagregantes en la diabetes. <b>2010</b> , 26, 24-28		1
100	NSAIDs and Cardiovascular Toxicity. <b>2010</b> , 323-336		
99	Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. <b>2010</b> , 6, 619-28		40
98	Aspirin Following Non-arteritic Ischaemic Optic Neuropathy: A Systematic Review and Meta-analysis. <b>2010</b> , 34, 14-19		3
97	Antiplatelet therapy in coronary heart disease prevention. <b>2011</b> , 29, 71-85		7
96	Effect of aspirin on mortality in the primary prevention of cardiovascular disease. <b>2011</b> , 124, 621-9		108
95	Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. <i>Canadian Journal of Cardiology</i> , <b>2011</b> , 27, 74-90	3.8	227

94	Keys to understanding the clinical significance of NNT and NNH. <b>2011</b> , 9, 400-401		
93	Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. <b>2011</b> , 91, 542-51		39
92	Antiplatelet therapy in acute coronary syndromes: implications for nursing practice. <b>2011</b> , 26, 239-49		2
91	Cost-utility of aspirin and proton pump inhibitors for primary prevention. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 218-25		38
90	The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. <i>BMJ Open</i> , <b>2011</b> , 1, e000363	3	25
89	Wound protectors reduce surgical site infection: a meta-analysis of randomized controlled trials. <i>Annals of Surgery</i> , <b>2012</b> , 256, 53-9	7.8	99
88	Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot. <i>Circulation Journal</i> , <b>2012</b> , 76, 1333-4	2.9	
87	[Do we adequately prescribe antiplatelet treatment to type 2 diabetic patients?]. <i>Semergen</i> , <b>2012</b> , 38, 360-5	1.9	
86	Long-term incidence of myocardial infarct, stroke, and mortality in patients operated on for abdominal aortic aneurysms. <i>Journal of Vascular Surgery</i> , <b>2012</b> , 55, 311-7	3.5	24
85	Coronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies. <i>Expert Review of Cardiovascular Therapy</i> , <b>2012</b> , 10, 1051-60	2.5	8
84	A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. <i>Annals of Pharmacotherapy</i> , <b>2012</b> , 46, 688-95	2.9	29
83	NNT, number needed to treat: does it have any real value?. <i>Climacteric</i> , <b>2012</b> , 15, 139-42	3.1	2
82	Gastrointestinal Bleeding: Antiplatelets and Anticoagulants. <b>2012</b> , 29-40		
81	MDCT in diagnosing acute aortic syndromes: reviewing common and less common CT findings. <i>Radiologia Medica</i> , <b>2012</b> , 117, 393-409	6.5	9
80	Effects of aspirin on cancer initiation and progression. <i>Expert Review of Anticancer Therapy</i> , <b>2013</b> , 13, 115-7	3.5	3
79	Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. <i>Journal of General Internal Medicine</i> , <b>2013</b> , 28, 1483-91	4	16
78	Process Improvement: VTE Prophylaxis in Hospitalized Patients. <i>Hospital Medicine Clinics</i> , <b>2013</b> , 2, e142-e157		
77	Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, S60-70	3.8	9

76	Use of antiplatelet agents in patients with atherosclerotic disease. <i>Postgraduate Medicine</i> , <b>2013</b> , 125, 19-30	3.7	2
75	Biased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 1678-1690	6.3	8
74	Antiplatelet/anticoagulant agents and chronic subdural hematoma in the elderly. <i>PLoS ONE</i> , <b>2013</b> , 8, e68732	3.7	60
73	Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status. <i>PLoS ONE</i> , <b>2014</b> , 9, e90286	3.7	50
72	Aspirin delimits platelet life span by proteasomal inhibition. <i>PLoS ONE</i> , <b>2014</b> , 9, e105049	3.7	13
71	Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. <i>Cancer Prevention Research</i> , <b>2014</b> , 7, 341-50	3.2	23
70	Aspirin-induced microscopic surface changes stimulate thrombopoiesis in rat megakaryocytes. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2014</b> , 20, 318-25	3.3	9
69	Aspirin resistance as cardiovascular risk after kidney transplantation. <b>2014</b> , 26, 237-241		1
68	Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 354-65	3.9	10
67	Orally given gastroprotective capsaicin does not modify aspirin-induced platelet aggregation in healthy male volunteers (human phase I examination). <i>Acta Physiologica Hungarica</i> , <b>2014</b> , 101, 429-37		4
66	Aspirin intake correlates with halted growth of sporadic vestibular schwannoma in vivo. <i>Otology and Neurotology</i> , <b>2014</b> , 35, 353-7	2.6	35
65	The Beneficial Biological Properties of Salicylic Acid. <i>Acta Facultatis Medicae Naissensis</i> , <b>2015</b> , 32, 259-265.	2	26
64	Determinants of inpatient costs of angina pectoris, myocardial infarction, and heart failure in a university hospital setting in Turkey. <i>Anatolian Journal of Cardiology</i> , <b>2015</b> , 15, 325-33	0.8	8
63	Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. <i>European Journal of Epidemiology</i> , <b>2015</b> , 30, 5-18	12.1	47
62	COX-2 inhibitors (coxibs). <b>2016</b> , 738-762		0
61	Multimorbidity in chronic disease: impact on health care resources and costs. <i>Risk Management and Healthcare Policy</i> , <b>2016</b> , 9, 143-56	2.8	199
60	Microparticle Shedding by Erythrocytes, Monocytes and Vascular Smooth Muscular Cells Is Reduced by Aspirin in Diabetic Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2016</b> , 69, 672-80	0.7	19
59	El ácido acetilsalicílico reduce la liberación de micropartículas eritrocitarias, monocitarias y de células del mículo liso vascular en pacientes diabéticos. <i>Revista Espanola De Cardiologia</i> , <b>2016</b> , 69, 672-680	1.5	33

58	Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 493-504	5.1	4
57	Early aspirin desensitization in unstable patients with acute coronary syndrome: Short and long-term efficacy and safety. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2016</b> , 5, 41-50	4.3	6
56	Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study. <i>Contemporary Clinical Trials Communications</i> , <b>2017</b> , 6, 105-114	1.8	5
55	PEG-400 Mediated an Efficient Green Synthesis of Isoxazolyl Indole-3-Carboxylic Acid Esters via Nentizescu Condensation Reaction and Their Anti-Inflammatory and Analgesic Activity. <i>ChemistrySelect</i> , <b>2017</b> , 2, 5110-5114	1.8	7
54	Gastrointestinal Complications of Antirheumatic Drugs. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2017</b> , 13, 411-452	0.3	1
53	Probiotics and Evidence-based Medicine: To All Involved: We have a Problem. <i>Journal of Clinical Gastroenterology</i> , <b>2018</b> , 52 Suppl 1, Proceedings from t, S4-S6	3	1
52	Methods of Determining Prognosis. <b>2018</b> , 213-230		
51	NSAIDs and Cardiovascular Toxicity. <b>2018</b> , 341-355		
50	Epidemiology of helicopter accidents: Trends, rates, and covariates. <i>Reliability Engineering and System Safety</i> , <b>2018</b> , 180, 373-384	6.3	11
49	Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 52	8.3	29
48	Should Evidence Come with an Expiration Date?. <i>Journal of General Internal Medicine</i> , <b>2019</b> , 34, 1356-1357	1.4	4
47	References. <b>2019</b> , 415-510		
46	Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: The FANCY study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2257-2266	6.7	3
45	Interplay Between Oxidative Stress, Cyclooxygenases, and Prostanoids in Cardiovascular Diseases. <i>Antioxidants and Redox Signaling</i> , <b>2021</b> , 34, 784-799	8.4	10
44	Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. <i>Signal Transduction and Targeted Therapy</i> , <b>2021</b> , 6, 94	2.1	68
43	Pretreatment with antiplatelet drugs improves the cardiac function after myocardial infarction without reperfusion in a mouse model. <i>Cardiology Journal</i> , <b>2021</b> , 28, 118-128	1.4	3
42	Welch-weighted Egger regression reduces false positives due to correlated pleiotropy in Mendelian randomization.		
41	Appropriateness of aspirin prescribing for primary and secondary prevention of cardiovascular disease in type 2 diabetes in different care settings. <i>Irish Journal of Medical Science</i> , <b>2021</b> , 1	1.9	1

40	Impact of time to resumption of antithrombotic therapy on outcomes after surgical evacuation of chronic subdural hematoma: A multicenter cohort study. <i>Journal of Clinical Neuroscience</i> , <b>2021</b> , 89, 389-396	2.2	0
39	Number Needed to Scan: Evidence-Based Point-of-Care Ultrasound (POCUS). <i>Cureus</i> , <b>2021</b> , 13, e17278	1.2	
38	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020330	6	1
37	Evidence reversals in primary care research: a study of randomized controlled trials. <i>Family Practice</i> , <b>2021</b> ,	1.9	
36	Bioactive Phytochemicals and Antioxidant Capacity of Wheatgrass Treated with Salicylic Acid under Organic Soil Cultivation. <i>Chemistry and Biodiversity</i> , <b>2021</b> , 18, e2000861	2.5	1
35	Behavioral Medicine and the Benefits of Healthcare: A Critical Appraisal and the Need for Exnovation. <b>2018</b> , 1069-1086		1
34	Cardiac disease in chronic uremia. <b>2004</b> , 765-790		1
33	Aspirin in Primary and Secondary Prevention of Cardiovascular Disease. <b>2010</b> , 117-129		1
32	NHG-Standaard Cardiovasculair risicomanagement. <b>2011</b> , 361-408		1
31	Nonsteroidal Anti-inflammatory Drugs. <b>2009</b> , 833-861		2
30	Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 725-9	0.6	10
29	Aspirin for everyone older than 50? Against. <i>BMJ, The</i> , <b>2005</b> , 330, 1442-3	5.9	15
28	Non-invasive characterisation of coronary lesion morphology by multi-slice computed tomography: a promising new technology for risk stratification of patients with coronary artery disease. <i>British Heart Journal</i> , <b>2001</b> , 85, 576-8		38
27	Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study. <i>British Heart Journal</i> , <b>2001</b> , 85, 578-80		8
26	Progressive ECG changes before the onset of atrial flutter in adult congenital heart disease patients. <i>British Heart Journal</i> , <b>2001</b> , 85, 703		10
25	Dissolution of tungsten coils leads to device failure after transcatheter embolisation of pathologic vessels. <i>British Heart Journal</i> , <b>2001</b> , 85, 703-4		13
24	Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice. <i>British Heart Journal</i> , <b>2001</b> , 86, 218-9		7
23	Understanding Drug Repurposing From the Perspective of Biomedical Entities and Their Evolution: Bibliographic Research Using Aspirin. <i>JMIR Medical Informatics</i> , <b>2020</b> , 8, e16739	3.6	7



22	Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug users. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 3811-6	5.6	19
21	Inhibitory effects of epigallocatechin-3-gallate on microsomal cyclooxygenase-1 activity in platelets. <i>Biomolecules and Therapeutics</i> , <b>2013</b> , 21, 54-9	4.2	18
20	Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study. <i>British Heart Journal</i> , <b>2001</b> , 86, 219-20		1
19	Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , <b>2003</b> , 21, 759-89		3
18	Coagulation, thrombosis, and coronary heart disease. <b>2005</b> , 466-479		
17	COX-2 inhibitors. <b>2006</b> , 1000-1015		
16	ATHEROSCLEROSIS AND THROMBOSIS IN DIABETES MELLITUS: NEW ASPECTS OF PATHOGENESIS. <b>2008</b> , 89-113		0
15	NHG-Standaard Cardiovasculair risicomanagement. <b>2009</b> , 106-152		2
14	ADVERSE CARDIOVASCULAR EFFECTS OF NON-CARDIOVASCULAR DRUGS. <b>2009</b> , 557-820		
13	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs). <b>2010</b> , 223-369		
12	Manejo de los antiagregantes en el perioperatorio. <b>2010</b> , 123-140		
11	calculated-10-years-risk-of-chd-primary-preventive-measures-in-medical-ward-ppukm-university-kebangsaan-malaysia- <i>Malaysian Journal of Pharmacy</i> , <b>2011</b> , 1, 336-344		0
10	Aspirin. 12-25		
9	Understanding Drug Repurposing From the Perspective of Biomedical Entities and Their Evolution: Bibliographic Research Using Aspirin (Preprint).		
8	Antiplatelet Effect of a Pulaimab [Anti-GPIIb/IIIa F(ab)2 Injection] Evaluated by a Population Pharmacokinetic-pharmacodynamic Model. <i>Current Drug Metabolism</i> , <b>2019</b> , 20, 1060-1072	3.5	
7	Phenome-scale causal network discovery with bidirectional mediated Mendelian randomization.		2
6	Does low-dose ASA help prevent cardiovascular events in women?. <i>Canadian Family Physician</i> , <b>2006</b> , 52, 319-21	0.9	
5	Do cyclooxygenase inhibitors increase risk of cardiovascular thrombotic events?. <i>Canadian Family Physician</i> , <b>2002</b> , 48, 1449-51	0.9	4

4	Is There A Role For Aspirin In Primary Prevention Of Ischemic Heart Disease In Hypertensive Patients?. <i>Malaysian Family Physician</i> , <b>2006</b> , 1, 27	0.5	
3	Using Entity Metrics to Understand Drug Repurposing. <i>AMIA Summits on Translational Science Proceedings</i> , <b>2020</b> , 2020, 377-382	1.1	
2	Welch-weighted Egger regression reduces false positives due to correlated pleiotropy in Mendelian randomization. <i>American Journal of Human Genetics</i> , <b>2021</b> , 108, 2319-2335	11	1
1	Methods of determining prognosis. 179-194		